SCHEMBL4024495

SCHEMBL4024495

Cc1cccc(C2C(C(=O)c3ccccc3)CN(CC(=O)N(C)C)CC2C(=O)c2ccccc2)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.43
DRD4 P21917 2/20 0.41
DRD3 P35462 2/20 0.41
HDAC4 P56524 1/20 0.41
GRIN2B Q13224 2/20 0.39
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
RORC P51449 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
PROKR1 Q8TCW9 1/20 0.37
DRD1 P21728 1/20 0.36
DRD5 P21918 1/20 0.36
EPHX1 P07099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024492 1.00 DRD2 (0.43) DRD2DRD4DRD3HDAC4GRIN2B
SCHEMBL4813149 0.90 KMO (0.42) DRD2DRD3GRIN2BKMT2AMEN1
SCHEMBL4019710 0.89 RORC (0.43) DRD4GRIN2BKMT2AMEN1RORC
SCHEMBL4019712 0.89 RORC (0.43) DRD4GRIN2BKMT2AMEN1RORC
SCHEMBL4024572 0.89 RORC (0.43) DRD4GRIN2BKMT2AMEN1RORC
SCHEMBL4020117 0.89 GRIN2B (0.40) DRD2DRD4DRD3GRIN2BDRD1
SCHEMBL4020120 0.89 GRIN2B (0.40) DRD2DRD4DRD3GRIN2BDRD1
SCHEMBL4749047 0.88 PARP1 (0.43)
SCHEMBL4021306 0.88 GRIN2B (0.43) DRD4GRIN2BRORC
SCHEMBL4021309 0.88 GRIN2B (0.43) DRD4GRIN2BRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 DRD2 3430/4885DRD4 2983/4885DRD3 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.